Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Castration-Resistant Prostate Cancer (mCRPC): early-phase trial registry
11 of 16 indexed Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 11 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Metastatic Castration-Resistant Prostate Cancer (mCRPC): 16 US clinical trials tracked, 11 recruiting.
Metastatic Castration-Resistant Prostate Cancer (mCRPC) is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition metastatic-castration-resistant-prostate-cancer-mcrpc
OPEN 11 | RECR 69% | LATE 3 | EARLY 13 | RANK #1060 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Deep Brain Stimulation (69% recruiting · 16 trials)
Metastatic Castration-Resistant Prostate Cancer (mCRPC) lists 11 open slots (69% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Castration-Resistant Prostate Cancer (mCRPC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Castration-Resistant Prostate Cancer (mCRPC) is recruiting above its size-band peers.
11 of 16 indexed trials (68.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials is spread across many organizations.
Novartis Pharmaceuticals accounts for 2 of 16 trials (12.5%). 15 distinct sponsors appear on at least one study for this condition label.
-
Typical Metastatic Castration-Resistant Prostate Cancer (mCRPC) enrolment sits around 345 participants.
Median target enrolment is 345 among the 16 trials that report a genuine target (sentinel values excluded). 4 of those (25%) plan for fewer than 100 participants.
-
Metastatic Castration-Resistant Prostate Cancer (mCRPC) research is mostly interventional.
16 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis
NCT05176483
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Merck Sharp & Dohme
NCT06136650
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
NCT03460977
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Dendreon
NCT06134232
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Regeneron Pharmaceuticals
NCT03972657
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics
NCT05107674
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Arsenal Biosciences
NCT07285694
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
K36 Therapeutics
NCT07103018
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Charles Drew University of Medicine and Science
NCT06615752
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Novartis Pharmaceuticals
NCT06004661
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
University of Oklahoma
NCT05806814
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Jiangsu HengRui Medicine Co.
NCT04691804
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Nuvation Bio
NCT06334432
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Xencor
NCT05032040
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
Novartis Pharmaceuticals
NCT06894511
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
Astellas Pharma Global Development
NCT01977651
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 4 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Castration-Resistant Prostate Cancer (mCRPC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Castration-Resistant Prostate Cancer (mCRPC) page
16 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novartis Pharmaceuticals sponsors the most Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials on record, review their full trial history before evaluating a specific study. See Novartis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Castration-Resistant Prostate Cancer (mCRPC) condition card totals 16 registered trials; most-linked intervention AAA617; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.